213 results
8-K
EX-99.1
YTEN
Yield10 Bioscience Inc
1 Apr 24
Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results
4:06pm
revenue to be recognized. Research and development expense was $8.3 million during the year ended December 31, 2023, an increase of $0.5 million … in 2022.
During the fourth quarter of 2023, research and development expense increased by $0.1 million from $1.9 million in the fourth quarter of 2022
8-K
EX-99.1
YTEN
Yield10 Bioscience Inc
14 Feb 24
Other Events
11:34am
related to Yield10’s continued research and development activities for different varieties of Camelina, the expected path to regulatory approvals
8-K
EX-99.1
YTEN
Yield10 Bioscience Inc
8 Feb 24
Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program
5:19pm
release which are not strictly historical, including, without limitation, expectations related to research and development activities, the expected
8-K
EX-99.1
y1hc0n lmx771p
14 Nov 23
Yield10 Bioscience Announces Third Quarter 2023 Financial Results
4:07pm
8-K
EX-99.1
041zsdxs77m3
11 Sep 23
Other Events
9:11am
8-K
EX-99.1
o20q3kjm6v7cps4uq3
14 Aug 23
Yield10 Bioscience Announces Second Quarter 2023 Financial Results
4:07pm
424B4
w4g4mpjz9pt6qrcu
11 Aug 23
Prospectus supplement with pricing info
5:09pm
424B3
dxja jpxka
18 Jul 23
Prospectus supplement
2:38pm
8-K
EX-99.1
l485atn3 6n
10 May 23
Yield10 Bioscience Announces First Quarter 2023 Financial Results
4:05pm
424B5
7us52
4 May 23
Prospectus supplement for primary offering
5:26pm